PRIVACY & SECURITY FORUM: A HIMSS EVENT
Boston, MA - December 5 - 7, 2016
Jeff R. Livingstone, PhD, is a Global Senior Director in the Enterprise Solutions Division, specializing in the Life Sciences and Healthcare vertical. He is principally responsible for driving new business growth through the development of industry-aligned solutions and services.
Livingstone is the Global Senior Director for the Unisys Enterprise Solutions division covering the Life Sciences and Healthcare industry worldwide. He brings over 30 years’ experience leading large scale change programs with global teams. His rare combination of knowledge about the science of drug discovery and molecular engineering, and deep cybersecurity and IT background, provide the necessary perspective to create highly impactful LSH solutions yielding clear, measurable results. Dr. Livingstone has held numerous roles during his multi-faceted career across sales, marketing, product and service development, program management, business development and corporate management.
Livingstone previously served as Asst. VP and North American Regional Head of CyberSecurity for Tech Mahindra where he was responsible for developing the North American CyberSecurity Practice. This included business development, delivery and fulfillment across all verticals, but with a heightened focus on Life Sciences (pharma, biotech, and medical devices). Prior to this role, he was responsible for developing the Life Sciences and Healthcare verticals for Pegasystems and Akamai Technologies.
Previous to Akamai, Dr. Livingstone was the GM and Global Head of the Pierce Milwaukee division of Fisher Scientific, where he was responsible for the entire global P&L. Prior to Fisher, he was Head of Product Marketing for CyberMedica, one of the very first large medical data analytics companies.
Livingstone has a PhD, Physical Biochemistry from the University of Wisconsin-Madison and a BS in Biochemistry from the University of Missouri-Columbia. He performed post-graduate work on new AIDS therapies at the NIH / Frederick Cancer Research Center and was part of a small team at Genentech responsible for creating the first anti-Her2 humanized antibody biotherapetic (Herceptin™). He is a specialist in physical biochemistry and biophysics and has published several reviewed articles in this area.